The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 19, 2016
Filed:
Dec. 13, 2011
Soon Myung Paik, Pittsburgh, PA (US);
Sung Kim, Gyeonggi-do, KR;
Won Ki Kang, Seoul, KR;
Jee Yun Lee, Seoul, KR;
Jae Moon Bae, Seoul, KR;
Tae Sung Sohn, Seoul, KR;
Jae Hyung Noh, Seoul, KR;
Min Gew Choi, Seoul, KR;
Young Suk Park, Seoul, KR;
Joon OH Park, Gyeonggi-do, KR;
SE Hoon Park, Seoul, KR;
Ho Yeong Lim, Gyeonggi-do, KR;
Sin Ho Jung, Chapel Hill, NC (US);
Soon Myung Paik, Pittsburgh, PA (US);
Sung Kim, Gyeonggi-do, KR;
Won Ki Kang, Seoul, KR;
Jee Yun Lee, Seoul, KR;
Jae Moon Bae, Seoul, KR;
Tae Sung Sohn, Seoul, KR;
Jae Hyung Noh, Seoul, KR;
Min Gew Choi, Seoul, KR;
Young Suk Park, Seoul, KR;
Joon Oh Park, Gyeonggi-do, KR;
Se Hoon Park, Seoul, KR;
Ho Yeong Lim, Gyeonggi-do, KR;
Sin Ho Jung, Chapel Hill, NC (US);
Samsung Life Public Welfare Foundation, Seoul, KR;
Abstract
The present invention relates to a marker for predicting a gastric cancer prognosis, a composition and a kit for predicting gastric cancer prognosis comprising an agent for measuring the expression level thereof, and a method for predicting gastric cancer prognosis using the marker. According to the present invention, gastric cancer prognosis may be predicted promptly and accurately, and an appropriate treatment plan can be determined based on the predicted prognosis, which has an advantage of contributing to significant reduction of death caused by gastric cancer. Particularly, according to the present invention, the survival rate can be remarkably increased by using the treatment method for a stage III gastric cancer patient to a patient who has been predicted to have a negative prognosis among stage Ib/II gastric cancer patients.